Two Sigma Advisers
BTAI icon

Two Sigma Advisers’s BioXcel Therapeutics BTAI Stock Holding History

Two Sigma Advisers’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-4,619
Closed -$187K – 2506
2023
Q3 		$187K Buy
+4,619
New +$467K ﹤0.01% 2110
2023
Q2 		– Sell
-3,588
Closed -$1.07M – 2405
2023
Q1 		$1.07M Buy
3,588
+1,750
+95% +$747K ﹤0.01% 1593
2022
Q4 		$632K Sell
1,838
-2,206
-55% -$533K ﹤0.01% 1781
2022
Q3 		$765K Sell
4,044
-2,156
-35% -$501K ﹤0.01% 1657
2022
Q2 		$1.31M Buy
6,200
+5,294
+584% +$1.11M ﹤0.01% 1451
2022
Q1 		$303K Buy
906
+100
+12% +$29K ﹤0.01% 2217
2021
Q4 		$262K Sell
806
-1,525
-65% -$654K ﹤0.01% 2184
2021
Q3 		$1.13M Sell
2,331
-1,744
-43% -$767K ﹤0.01% 1555
2021
Q2 		$1.9M Sell
4,075
-931
-19% -$507K 0.01% 1318
2021
Q1 		$3.46M Buy
5,006
+3,831
+326% +$3.08M 0.01% 1019
2020
Q4 		$869K Buy
+1,175
New +$915K ﹤0.01% 1632
2020
Q3 		– Sell
-1,700
Closed -$1.44M – 2411
2020
Q2 		$1.44M Buy
+1,700
New +$1.11M ﹤0.01% 1394

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Two Sigma Advisers's BTAI Position: Q4 2023 in Review

Two Sigma Advisers sold out of BioXcel Therapeutics (BTAI) in Q4 2023, closing a stake of 4,619 shares — an estimated $187K sold.

Two Sigma Advisers first reported a position in BTAI in Q2 2020 and held it in 12 quarters. The position peaked at $3.46M in Q1 2021. 73 funds tracked by Wall St. Rank hold BTAI as of Q4 2023.

  • Two Sigma Advisers reported no remaining BioXcel Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Two Sigma Advisers sold 4,619 BioXcel Therapeutics shares in Q4 2023, an estimated $187K.
  • Two Sigma Advisers first reported a position in BioXcel Therapeutics in Q2 2020 and held it in 12 quarters.
  • Two Sigma Advisers's BioXcel Therapeutics position peaked at $3.46M in Q1 2021.
  • 73 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q4 2023.

Based on Two Sigma Advisers's 13F filing for Q4 2023, filed 14 Feb 2024.